Ichnos Glenmark Announces Promising Phase I Results for ISB 830, a Potential Breakthrough Treatment for Multiple Myeloma
Ichnos Glenmark to Present Phase I Study Data for Myeloma Drug Candidate ISB 830 Ichnos Glenmark, a subsidiary of Glenmark…
Ichnos Glenmark
Read More